- Home
- ICCC vs BEAT Comparison
ICCC vs BEAT Comparison
Compare ICCC & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- BEAT
- Stock Information
- Founded
- ICCC 1982
- BEAT 2015
- Country
- ICCC United States
- BEAT United States
- Employees
- ICCC N/A
- BEAT N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- ICCC Health Care
- BEAT Technology
- Exchange
- ICCC Nasdaq
- BEAT Nasdaq
- Market Cap
- ICCC 61.3M
- BEAT 51.1M
- IPO Year
- ICCC 1987
- BEAT 2021
- Fundamental
- Price
- ICCC $5.90
- BEAT $1.47
- Analyst Decision
- ICCC
- BEAT Buy
- Analyst Count
- ICCC 0
- BEAT 1
- Target Price
- ICCC N/A
- BEAT $8.00
- AVG Volume (30 Days)
- ICCC 27.4K
- BEAT 158.5K
- Earning Date
- ICCC 08-12-2025
- BEAT 08-13-2025
- Dividend Yield
- ICCC N/A
- BEAT N/A
- EPS Growth
- ICCC N/A
- BEAT N/A
- EPS
- ICCC N/A
- BEAT N/A
- Revenue
- ICCC $27,302,766.00
- BEAT N/A
- Revenue This Year
- ICCC N/A
- BEAT N/A
- Revenue Next Year
- ICCC N/A
- BEAT N/A
- P/E Ratio
- ICCC N/A
- BEAT N/A
- Revenue Growth
- ICCC 28.29
- BEAT N/A
- 52 Week Low
- ICCC $3.34
- BEAT $1.45
- 52 Week High
- ICCC $7.60
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- ICCC 50.09
- BEAT 44.15
- Support Level
- ICCC $6.14
- BEAT $1.51
- Resistance Level
- ICCC $6.58
- BEAT $1.76
- Average True Range (ATR)
- ICCC 0.25
- BEAT 0.13
- MACD
- ICCC -0.07
- BEAT -0.00
- Stochastic Oscillator
- ICCC 1.15
- BEAT 14.29
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.